Health and Me

Rachel V Thomas

New Drug Boosts Survival Rate In Patients With Metastatic Pancreatic Cancer

<span>Pancreatic cancer</span> has long been one of the toughest challenges in oncology. With a five-year survival rate hovering around 13 per cent and recurrence rates approaching 80 per cent after treatment, the odds have historically been stacked against patients.

However, an experimental drug called <span>daraxonrasib</span>, developed by the US-based late-stage clinical oncology company <span>Revolution Medicines</span>, has shown promise in improving survival rates in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

“For patients with metastatic pancreatic cancer, new treatment options are urgently needed to increase survival time and improve quality of life,” said Brian M. Wolpin, professor of medicine at Harvard Medical School, and principal investigator for the trial.

Wolpin noted that the study “indicates that daraxonrasib provides a clear and highly meaningful step forward for patients with pancreatic cancer who have experienced progression on prior treatment, typically chemotherapy.”

Daraxonrasib is a once-daily oral pill that demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with standard intravenous chemotherapy.

Daraxonrasib, described as a multi-selective inhibitor of RAS(ON) proteins, is the first investigational drug in a new class of RAS inhibitors designed to target a broad spectrum of cancer-causing RAS mutations.

In the clinical trial, daraxonrasib showed a median overall survival of 13.2 months, compared with 6.7 months for chemotherapy.

The drug was generally well tolerated and showed a manageable safety profile, with no new safety concerns identified.

Daraxonrasib works by blocking KRAS signalling proteins that drive tumor growth.

Pancreatic cancer is considered one of the most RAS-addicted cancers, with more than 90 per cent of patients carrying tumours driven by RAS protein mutations.

Also read: <a href="https://www.healthandme.com/health-wellness/former-us-senator-ben-sasse-opens-up-about-battle-with-terminal-stage-4-pancreatic-cancer-article-154042531" data-type="tilCustomLink">Former US Senator Ben Sasse Opens Up About Battle With Terminal Stage 4 Pancreatic Cancer</a>

<h2>Daraxonrasib: The Clinical Trial</h2>

The controlled Phase 3 clinical trial evaluated daraxonrasib in patients with previously treated metastatic PDAC.

The trial included patients with pancreatic tumours carrying a wide range of RAS variants, as well as patients without identified RAS mutations.

The results showed that daraxonrasib significantly improved overall survival in patients with previously treated metastatic pancreatic cancer.

Similar RAS-targeting drugs are now being developed by other companies for pancreatic, lung, and colon cancers.

“It’s the beginning, not the end,” said Elizabeth Jaffee in comments to The New York Times.

According to the company, “Daraxonrasib was generally well tolerated, with a manageable safety profile and with no new safety signals.”

Prior studies with daraxonrasib have shown that rash is the most common side effect, with mouth sores, diarrhea, nausea, and vomiting also common. 

Also read: <a href="https://www.healthandme.com/health-news/india-gets-its-first-alzheimers-drug-know-all-about-eli-lillys-lormalzi-article-154316399" data-type="tilCustomLink">India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi</a>

Based on the first interim analysis, all progression-free survival and overall survival results are now considered final.

Revolution Medicines said it plans to submit the data to global regulators, including the US Food and Drug Administration (FDA), as part of a future New Drug Application under a Commissioner’s National Priority Voucher.

The findings are also expected to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

<h2>What Is Pancreatic Cancer? Know The Warning Signs</h2>

Pancreatic cancer typically begins in the ducts of the organ and can rapidly spread from there to the rest of the organ. Early-stage pancreatic tumors do not show up on imaging tests, making this version of the disease difficult to diagnose until it infects other organs.

The prevention and early detection remain vital.

Experts warn that pancreatic cancer often masquerades as common ailments, delaying diagnosis. Here are some early symptoms that should never be ignored:

<ul><li>Abdominal or back pain that worsens over time or eases when leaning forward.</li><li>Unexplained weight loss without changes in diet or exercise.</li><li>Jaundice, including yellowing of the eyes and skin, sometimes with intense itching.</li><li>Changes to urine or stool, such as dark urine or pale, greasy stools.</li><li>New-onset diabetes without obvious risk factors.</li><li>Persistent fatigue unrelated to poor sleep or lifestyle</li></ul>These symptoms often appear in combination and warrant immediate medical attention — particularly for those with a family history of pancreatic cancer.

Health Conditions A-Z

health

new-drug-boosts-survival-rate-in-patients-with-metastatic-pancreatic-cancer

Pancreatic Cancer

daraxonrasib

oral pill for pancreatic cancer

Revolution Medicines

US FDA

worried-about-weight-gain-after-wegovy-mounjaro-this-us-fda-approved-daily-pill-may-help

Worried About Weight Gain After Wegovy, Mounjaro? This US FDA-Approved Daily Pill May Help

hantavirus-outbreak-critically-ill-french-patient-on-artificial-lung-support

Hantavirus Outbreak: Critically Ill French Patient On Artificial Lung Support

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Pancreatic cancer has long been one of the toughest challenges in oncology. With a five-year survival rate hovering around 13 per cent and recurrence rates approaching 80 per cent after treatment, the odds have historically been stacked against patients.However, an experimental drug called daraxonrasib, developed by the US-based late-stage clinical oncology company Revolution Medicines, has shown promise in improving survival rates in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).“For patients with metastatic pancreatic cancer, new treatment options are urgently needed to increase survival time and improve quality of life,” said Brian M. Wolpin, professor of medicine at Harvard Medical School, and principal investigator for the trial.Wolpin noted that the study “indicates that daraxonrasib provides a clear and highly meaningful step forward for patients with pancreatic cancer who have experienced progression on prior treatment, typically chemotherapy.”What Is Daraxonrasib?Daraxonrasib is a once-daily oral pill that demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with standard intravenous chemotherapy.Daraxonrasib, described as a multi-selective inhibitor of RAS(ON) proteins, is the first investigational drug in a new class of RAS inhibitors designed to target a broad spectrum of cancer-causing RAS mutations.In the clinical trial, daraxonrasib showed a median overall survival of 13.2 months, compared with 6.7 months for chemotherapy.The drug was generally well tolerated and showed a manageable safety profile, with no new safety concerns identified.Daraxonrasib works by blocking KRAS signalling proteins that drive tumor growth.Pancreatic cancer is considered one of the most RAS-addicted cancers, with more than 90 per cent of patients carrying tumours driven by RAS protein mutations.Also read: Former US Senator Ben Sasse Opens Up About Battle With Terminal Stage 4 Pancreatic CancerDaraxonrasib: The Clinical TrialThe controlled Phase 3 clinical trial evaluated daraxonrasib in patients with previously treated metastatic PDAC.The trial included patients with pancreatic tumours carrying a wide range of RAS variants, as well as patients without identified RAS mutations.The results showed that daraxonrasib significantly improved overall survival in patients with previously treated metastatic pancreatic cancer.Similar RAS-targeting drugs are now being developed by other companies for pancreatic, lung, and colon cancers.“It’s the beginning, not the end,” said Elizabeth Jaffee in comments to The New York Times.What are the side effects?According to the company, “Daraxonrasib was generally well tolerated, with a manageable safety profile and with no new safety signals.” Prior studies with daraxonrasib have shown that rash is the most common side effect, with mouth sores, diarrhea, nausea, and vomiting also common. Also read: India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s LormalziFDA fast-tracks Daraxonrasib Based on the first interim analysis, all progression-free survival and overall survival results are now considered final.Revolution Medicines said it plans to submit the data to global regulators, including the US Food and Drug Administration (FDA), as part of a future New Drug Application under a Commissioner’s National Priority Voucher.The findings are also expected to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.What Is Pancreatic Cancer? Know The Warning SignsPancreatic cancer typically begins in the ducts of the organ and can rapidly spread from there to the rest of the organ. Early-stage pancreatic tumors do not show up on imaging tests, making this version of the disease difficult to diagnose until it infects other organs.The prevention and early detection remain vital.Experts warn that pancreatic cancer often masquerades as common ailments, delaying diagnosis. Here are some early symptoms that should never be ignored:Abdominal or back pain that worsens over time or eases when leaning forward.Unexplained weight loss without changes in diet or exercise.Jaundice, including yellowing of the eyes and skin, sometimes with intense itching.Changes to urine or stool, such as dark urine or pale, greasy stools.New-onset diabetes without obvious risk factors.Persistent fatigue unrelated to poor sleep or lifestyleThese symptoms often appear in combination and warrant immediate medical attention — particularly for those with a family history of pancreatic cancer.

new drug boosts survival rate in patients with metastatic pancreatic cancer

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

New Drug Boosts Survival Rate In Patients With Metastatic Pancreatic Cancer

Hantavirus Outbreak: Critically Ill French Patient On Artificial Lung Support

India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi

Another Norovirus Outbreak Confirmed Aboard Cruise Ship In France; Over 1,700 People Trapped

Health Conditions A-Z

New Drug Boosts Survival Rate In Patients With Metastatic Pancreatic Cancer

Worried About Weight Gain After Wegovy, Mounjaro? This US FDA-Approved Daily Pill May Help

Hantavirus Outbreak: Critically Ill French Patient On Artificial Lung Support